Browse All

Current Filters

CLEAR FILTER x

TITLE

Safety and Efficacy of Riliprubart, an Activated C1s-complement Inhibitor in CIDP: 76-week Phase Two Trial Results

Author:Querol, Luis   Lewis, Richard A.   Hartung, Hans-Peter   van Doorn, Pieter A.   Lin, Jie   Dionne, Annie   Attarian, Shahram   Wallstroem, Erik   Auwarter, Kristen   Lu, Yi   Alonso-Alonso, Miguel   Atassi, Nazem   Hughes, Richard A. C.   

Session Name:S2: Updates on Motor Neuron and Peripheral Nerve Disorders  

Topic:Aging, Dementia, and Behavioral Neurology  

Program Number:S2.008  

Author Institution:

Riliprubart Phase Three MOBILIZE and VITALIZE Trials for CIDP are Actively Enrolling Globally

Author:Sommer, Claudia   Querol, Luis   Allen, Jeffrey   Merkies, Ingemar S.J.   van Doorn, Pieter A.   Wallstroem, Erik   Lu, Yi   Xiong, Li   Alonso-Alonso, Miguel   Atassi, Nazem   Lewis, Richard A.   

Session Name:P1: Neuromuscular and Clinical Neurophysiology (EMG): Autoimmune Neuropathies  

Topic:Multiple Sclerosis  

Program Number:P1.020  

Author Institution: